KORU Medical Systems filings document a Nasdaq-listed medical technology issuer focused on large-volume subcutaneous infusion products. The disclosures identify its common stock, operating results, earnings-release exhibits, non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS, and the Freedom System product family used in home self-administration and ambulatory infusion settings.
Its SEC record also covers proxy governance, board and stockholder-meeting procedures, officer and compensation arrangements, and material agreements tied to the business. Recent 8-K filings describe credit-facility arrangements and manufacturing and supply agreements for subassemblies, needle sets, and tubing products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.71%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
FAQ
How many KORU Medical Systems (KRMD) SEC filings are available on StockTitan?
StockTitan tracks 87 SEC filings for KORU Medical Systems (KRMD), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for KORU Medical Systems (KRMD)?
The most recent SEC filing for KORU Medical Systems (KRMD) was filed on August 6, 2025.